Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review - 13/06/23
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Immune-Mediated Necrotizing Myopathy (IMNM) after vaccination has been reported previously, however it is rare after COVID-19 vaccination. We report the first case of IMNM two weeks after vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine. There was a probable temporal relationship between the COVID-19 vaccination and the development of IMNM due to lack of known causative factors for IMNM. This may have been due to 1) autoimmunity directly caused by the vaccine, 2) exacerbation of autoimmunity triggered by the vaccine or 3) autoimmune syndrome triggered by the vaccine adjutants. Further studies are needed to assess the underlying mechanisms.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Myositis, COVID-19, Vaccines, Rhabdomyolysis, Necrotizing autoimmune myopathy
Mappa
Vol 179 - N° 6
P. 630-635 - giugno 2023 Ritorno al numero
Articolo precedente
- New insights for predicting surgery outcome in patients with temporal lobe epilepsy. A systematic review
- M. Baciu, L. O'Sullivan, L. Torlay, S. Banjac
- Subacute monomelic radiculoplexus neuropathy following Comirnaty© (Pfizer-BioNTech COVID-19) vaccination: A case report
- M. Coly, A. Balcerac, N. Brasseur, M. Sallansonnet-Froment, C. Tafani, I. Taifas, M.L. Bréchemier, E. Drouard, V. Foissaud, P. Vest, C. Vandendries, F. Bompaire, K. Bihan, D. Ricard
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.